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28 and were not evaluable for engraftment. Primary graft
failure occurred in 15 pts (35%) and 6 pts received a second
UCBT (only one pt is alive). Two other pts are alive with
autologous recovery (Osteopetrosis). Partial engraftment
(ANC 	 500/ul) occurred in 6 pts and all of them died. Acute
GVHD grade II-IV occurred in 15/28 pts (II: 2 pts, III: 8 pts;
IV: 5 pts) and C-GVHD in 11/20 pts (3 limited; 8 extensive).
Mucositis grade II-IV: 26 pts (III: 15 pts; IV: 3 pts). Arterial
hypertension and viral infections were also frequent complications.
VOD occurred in 4 pts (2 moderate; 1 severe). TRMwas very high in
this group reaching 46% (23 pts). Twenty-eight pts died in a median
of 38 days after UCBT (range 4–226). Main causes of death: infec-
tions: 20 pts (aggressive bacterial, fungal, and toxoplasmosis infec-
tions); bleeding: 3 pts; GVHD: 4 pts; and other: 1 pt. More than 70%
of our pts have bone marrow failures or osteopetrosis and this may
explain the high incidence of rejection and transplant relatedmortality
in this group of pts. Acute and chronic GVHD occurred with more
severity than expected for UCBT. We postulate that viral or other
infectious agents frequently found in our pts prior to transplant may
exacerbate this complication.
355
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SCT is the treatment of choice for FA patients (pts). These pts are
particularly hypersensitive to alkylating agents and radiation. In order
to decrease toxicity and maintain engraftment we have progressively
decreased the dose of CY during the last 20 years. In this study we
report our experience using the dose of CY 60 mg/kg in 40 pts
transplanted between 07/99–04/05. Median age : 9 years (5–29).
Previous blood transfusions: 0–101 (M: 5UI). Previous treatment with
androgens: 15/40 pts. All pts had pancytopenia and received either
unmanipulated bone marrow (39 pts) or cord blood (1 pt) from HLA
identical donors (siblings: 33 pts, other related: 7 pts). Preparatory
regimen consisted of CY 15 mg/kg/day  4. GVHD prophylaxis:
cyclosporine and methotrexate. TNC infused: 0, 97- 7, 3  108/kg
(M: 4, 05). The regimen was well tolerated with no transplant related
mortality (TRM). Thirty-eight pts (95%) are alive and well between
179–2250 days after SCT (M: 872 days). Median time to ANC
	500/ul: 19 days (11–57) and to platelets 	20.000/ul: 21 days (14–
57). Mucositis grades II–IV occurred in 92% of pts (II: 10 pts; III: 25
pts, IV: 1 pt). Mild VOD: 2 pts. Arterial hypertension was a frequent
complication. A-GVHD grade II-III occurred in 4/39 pts and C-
GVHD (extensive) in one pt. Primary graft failure (GF) occurred in
one pt (HLA identical sibling, 11 previous blood transfusions). He
received a second BMT from the same donor with no engraftment
and then a third BMT from another HLA identical sibling. He is now
187 days after BMT, independent of blood transfusion but with a slow
hematological recovery. Four pts (donors: 2 other related and 2
siblings) had a late GF on day 156, 202,  287, and 365 after
SCT. Three pts received a second SCT from the same donors and
they all engrafted. Two pts are alive and well with normal hemato-
logical counts on D 538 and 1203 after second SCT. Two pts
died: 1 after second SCT (day 98) due to A-GVHD, infection, and
cerebral venous sinus thrombosis. The other pt died on day918 due
to infections and complications related to rejection (29 years, 101
previous blood transfusions). We conclude that the use of CY 60
mg/kg in the preparatory regimen led to a better survival, no trans-
plant related mortality, and low incidence of both acute and chronic
GVHD. Graft failure occurred in 5 pts but 3 pts were rescued with
another transplant. This regimen can be offered safely to pts with
Fanconi anemia who have a related HLA identical donor.
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Banked, unrelated donor umbilical cord blood (UCB) increases
access to transplant by providing a source of hematopoietic stem
cells for patients (pts) lacking a family donor. We present outcomes
of 97 pediatric (ped) AML pts transplanted from 1995–2005. At
transplant, 51 pts were in Relapse or Refractory (RR) disease while
46 were in CR1/2 (CR). By low resolution HLA A/B  high-
resolution DRB1 typing, UCB units transplanted to RR pts were
3/6 (18%), 4/6 (45%), 5/6 (31%), or 6/6 (6%) matched and those
to CR pts were 4/6 (67%) or 5/6 (33%). The median age of RR and
CR pts was 8.4 and 9.4 years. Ethnic minorities comprised 35.3%
of RR and 34.8% of CR pts. Thirteen RR and 2 CR had prior auto-
or allo-transplants. The median total nucleated cell (TNC) doses
infused in RR and CR pts were 4.4 and 3.8  107/kg. All pts
received myeloablative regimens. RR pts receiving Melphalan con-
taining regimens (Bu/Mel/ATG or Flu/Mel/ATG or TBI/Mel/
ATG) were grouped as RR_Melve (n  33) and the rest receiving
TBI/Cy/ATG as RR_Melve (n  18). CR pts receiving TBI
containing regimens (TBI/Cy/ATG or TBI/Mel/ATG) were
grouped as CR_TBIve (n  29) and the rest receiving Bu/Mel/
ATG or Flu/Mel/ATG or Flu/Bu/Mel/ATG as CR_TBI-ve (n 
17). GVHD prophylaxis was Cyclosporinemethylprednisone in
94.8% The TNC dose, HLA match level, age, minority propor-
tion, and GVHD prophylaxis were similar between the RR and CR
pts. The probabilities of overall survival (OS) were estimated by
Kaplan-Meier analysis and compared using log-rank test. The 3
year probability of OS in the RR and CR was 28% and 48%.
AGVHD (Grade 2–4) was seen in 21.6% of RR and 21.7% of CR
pts and CGVHD in 6% and 7% of RR and CR pts. Deaths were
due to relapse, infection, and organ failure Within RR and CR the
impact of cytoreductive regimen was signiﬁcant. Three year prob-
ability of OS in CR_TBIve was signiﬁcantly higher (60%) than of
CR_TBIve (28%) pts (P  .014). The 3 year probability of OS in
RR_Melve was higher (39%) than of RR_Melve (11%) but the
difference did not reach statistical signiﬁcance(P  .132). We
conclude that for ped pts with AML lacking a family donor, UCB
is an excellent source of hematopoietic stem cells for those in
remission as well as those with high risk relapsed or refractory
disease. Cytoreductive regimen inﬂuences outcomes in both
groups of pts with more favorable outcomes in CR pts prepared
with TBI containing regimens and in refractory/relapsed pts pre-
pared with melphalan containing regimens.
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Objective: To evaluate the results of second allogeneic trans-
plantation after UCBT failed to engraft. Methods: Between No-
vember 1995 and July 2005, 116 UCBT were carried out at
Children’s Memorial Hospital of which 18 required second trans-
plantation (from failure to engraft, or relapse). Ten patients with
graft failure following a myeloablative cytoreduction regimen sub-
sequently received another transplant of unrelated cord blood (n
7), matched sibling marrow (n  1), marrow from a haploidentical
sibling (n  1), or matched sibling peripheral stem cells (n  1).
Underlying diseases for these 10 patients included AML (n  4),
Thalassemia (n  2), and 1 each of Myelodysplasia, Fanconi ane-
mia, Osteopetrosis, and ALL. Preparative conditioning prior to the
second transplant included Fludarabine 120–150 mg/m2 (n  5);
VP, Cy (n  2), or ATG (n  1). The 2 Thalassemia patients
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